Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Intra-Cellular Therapies Inc shares valued at $4,375,659 were sold by Mates Sharon on Dec 04 ’24. At $85.80 per share, Mates Sharon sold 51,000 shares. The insider’s holdings dropped to 1,070,329 shares worth approximately $136.06 million following the completion of this transaction.
Also, Mates Sharon sold 51,697 shares, netting a total of over 4,346,842 in proceeds. Following the sale of shares at $84.08 each, the insider now holds 1,070,329 shares.
Before that, Mates Sharon had added 51,697 shares to its account. In a trade valued at $4,343,616, the Officer bought Intra-Cellular Therapies Inc shares for $84.02 each.
As published in a research note from Canaccord Genuity on January 31, 2025, Intra-Cellular Therapies Inc [ITCI] has been rated down from a Buy to a Hold and the price target has been revised to $132 from $119. Analysts at Piper Sandler upgraded the stock from ‘”a Neutral”‘ to ‘”an Overweight”‘ outlook in a report released in early September. As of January 03, 2024, Robert W. Baird has initiated its “an Outperform” rating for ITCI. Earlier on December 11, 2023, TD Cowen initiated its rating. Their recommendation was “an Outperform” for ITCI stock.
Analyzing ITCI Stock Performance
During the last five days, there has been a surge of approximately 0.09%. Over the course of the year, Intra-Cellular Therapies Inc shares have jumped approximately 52.20%. Shares of the company reached a 52-week high of $128.00 on 01/13/25 and a 52-week low of $80.82 on 01/07/25. A 50-day SMA is recorded $100.05, while a 200-day SMA reached $80.96. Nevertheless, trading volume fell to 1.8 million shares from 2.11 million shares the previous day.
Support And Resistance Levels for Intra-Cellular Therapies Inc (ITCI)
According to the 24-hour chart, there is a support level at 127.00, which, if violated, would cause prices to drop to 126.88. In the upper region, resistance lies at 127.25. The next price resistance is at 127.38. RSI (Relative Strength Index) is 84.18 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.03, which suggests the price will decrease in the coming days. Percent R is at 33.79%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
